|
**Overview**: Below 45 Female Radiology Panel**Introduction**: The Below 45 Female Radiology Panel is a diagnostic tool designed for health screening in women under 45 years using serum samples and radiology. In India, women in this age group face high NCD burden (diabetes ~10-15 percent, dyslipidemia, hypertension, anemia, cervical/breast cancer risks), with underdiagnosis in rural/low-SES populations due to limited preventive care access. Symptoms may be absent in early stages, but complications include cardiovascular disease, infertility, or malignancy. Per preventive medicine practices aligned with ICMR and National Health Mission guidelines, the test employs spectrophotometry for biochemical markers over 1-2 days with high sensitivity/specificity, combined with radiology (chest X-ray, ECG) for basic assessment. This diagnostic falls under routine health check and targets women under 45 for annual screening, addressing early detection of metabolic/cardiorespiratory risks to guide lifestyle interventions. With high morbidity from underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing NCD burden in women. Its combined approach ensures reliable screening in India's diverse settings.**Other Names**: Female Rad Pnl.**FDA Status**: FDA approved, CLIA certified for biochemistry/radiology, compliant with 2025 standards.**Historical Milestone**: Developed as gender-specific preventive packages; in India, promoted with women's health initiatives.**Purpose**: The test screens for 5 parameters including fasting glucose to guide health assessment in women under 45, detect early NCD risks, inform interventions.**Test Parameters**: 1. Fasting Glucose, 2. Total Cholesterol, 3. Creatinine, 4. Chest X-Ray, 5. ECG.**Pretest Condition**: Fasting 10-12 hours required; patients should report any symptoms or family history of NCDs.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on lifestyle, menstrual history, family NCDs, symptoms.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated NCDs including cardiovascular complications, benefits of early detection, and minimal discomfort from blood draw/imaging.**Procedural Considerations**: The test involves sample processing using spectrophotometry and radiology by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days. Facilities must maintain controlled environments, adhere to quality assurance protocols, and follow safety guidelines for imaging.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage, hemolysis, or recent meals can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible NCD risks, necessitating further investigation. Normal may require follow-up in high-risk individuals.**Specialist Consultation**: General physicians or gynecologists should be consulted for interpretation and counseling.**Additional Supporting Tests**: HbA1c, lipid profile extension for confirmation.**Test Limitations**: May miss early subclinical disease or require repeat screening; comprehensive approach required.**References**: ICMR NCD Guidelines 2023, Women's Health Studies India 2024. |
